Core Insights - Pfizer reported fourth-quarter results that exceeded estimates despite declining demand for Covid products, while reaffirming its modest 2026 guidance that unsettled investors in December [1][5]. Financial Performance - Pfizer's fourth-quarter revenue was $17.56 billion, a decrease of approximately 1% year-over-year, primarily due to reduced demand for its Covid vaccine and Paxlovid [3][10]. - The company recorded a net loss of $1.65 billion, or 29 cents per share, compared to a net income of $410 million, or 7 cents per share, in the same quarter the previous year [4]. - Adjusted earnings per share were reported at 66 cents, surpassing the expected 57 cents [10]. Future Guidance - For 2026, Pfizer expects adjusted profit to range between $2.80 and $3 per share, with revenue projected to be between $59.5 billion and $62.5 billion, indicating flat sales compared to 2025 [5]. - The anticipated decline in revenue includes a projected drop of about $1.5 billion in sales from Covid products, expected to total $5 billion [5][6]. Strategic Initiatives - Pfizer is pursuing long-term investments, including a $10 billion acquisition of obesity biotech Metsera, to mitigate the impact of declining Covid product sales and older drug revenues [2]. - The company aims to cut costs by approximately $7.7 billion by the end of 2027 through two separate initiatives [3]. Market Dynamics - Pfizer faces an expected $1.5 billion year-over-year decline in sales due to certain products losing market exclusivity, with increased competition affecting blockbuster drugs like Prevnar [6]. - The company is also dealing with price and margin compression, as indicated by CFO Dave Denton, due to deeper discounts in its Medicaid business as part of a drug pricing agreement [7]. Regulatory Environment - Under a recent agreement, Pfizer will sell existing drugs to Medicaid patients at the lowest price offered in other developed countries and ensure similar pricing for new drugs for Medicare, Medicaid, and commercial payers, in exchange for a three-year exemption from tariffs [8]. - Pfizer's Xeljanz and Xeljanz XR have been selected for the third round of Medicare drug price negotiations, with new prices set to take effect in 2028 [9].